gallopamil has been researched along with 1-hexadecyl-2-acetyl-glycero-3-phosphocholine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kübler, W; Neumann, FJ; Ott, I; Rauch, B; Richardt, G; Tillmanns, H; Zimmermann, R | 1 |
Alabaster, VA; Cheeseman, HE; Cooper, K; deSouza, RN; Keir, RF; Parry, MJ | 1 |
1 trial(s) available for gallopamil and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Article | Year |
---|---|
Effect of gallopamil on neutrophil function: experimental and clinical studies.
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Gallopamil; Humans; In Vitro Techniques; Neutrophils; Platelet Activating Factor; Superoxides; Tetradecanoylphorbol Acetate | 1992 |
1 other study(ies) available for gallopamil and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Article | Year |
---|---|
Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Topics: Administration, Oral; Animals; Aorta; Azepines; Blood Platelets; Brain; Calcium Channels, L-Type; Capillary Permeability; Cattle; Dihydropyridines; Diltiazem; Gallopamil; Guinea Pigs; Hypotension; Imidazoles; In Vitro Techniques; Kinetics; Male; Membranes; Mice; Mice, Inbred Strains; Muscle Contraction; Muscle Proteins; Nitrendipine; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Potassium Chloride; Rabbits; Rats; Rats, Sprague-Dawley; Skin; Triazoles; Tritium | 1994 |